Johnson & Johnson (JNJ) earnings call transcripts

Management framed Q3 as sequential acceleration toward durable growth, while acknowledging MedTech execution fell below expectations and requires near-term repair.

Management framed the quarter as broad pharmaceutical momentum offsetting a temporary MedTech cardiovascular setback, with launch confidence intact.

Management framed Q1 as evidence that portfolio momentum is accelerating, with new launches and pipeline optionality supporting long-term growth.

Management framed 2025 as the launch point for accelerated growth, supported by portfolio reshaping, innovation, and multiple emerging blockbusters.

Management framed the quarter as proof of a durable growth cycle, while using the Orthopaedics separation to sharpen portfolio focus.

Management portrayed diversified innovation as offsetting STELARA erosion, with second-half acceleration supported by launches and a higher 2025 outlook.

Management framed Q1 as proof of portfolio resilience despite STELARA erosion, while acknowledging MedTech execution and tariff uncertainties.

Management framed 2025 as a year of disciplined resilience, using portfolio diversification and cost actions to offset major STELARA headwinds.

Management framed the quarter as evidence that portfolio-shifting toward innovative growth markets is offsetting Stelara erosion, China pressure, and litigation uncertainty.

Management framed Innovative Medicine as accelerating through launches and pipeline breadth, while acknowledging MedTech execution issues and a lower full-year growth outlook.

Management portrayed a strong strategic start, with launch momentum and pipeline progress outweighing temporary phasing, stocking and competitive pressures.

Management framed 2024 as a strong launch-and-procedure-recovery year, while acknowledging MedTech margin pressure and a milder XARELTO decline.